Albendazole

CLINICAL USE

  • Treatment of

    Echinococcus granulosus
    (hydatid disease), in combination with
    surgery

  • Treatment of nematode infections

    DOSE IN NORMAL RENAL FUNCTION


    Echinococcus granulosus:

  • >60 kg: 400 mg twice daily for 28 days
  • <60 kg: 15 mg/kg in 2 divided doses to a

    maximum of 800 mg daily
    Treatment of nematode infections: 400 mg as
    a single dose

    PHARMACOKINETICS


  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    265.3
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    70
  • %Excreted unchanged in urine &nbsp &nbsp :
    <1
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
    No data
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
    8–12 (metabolite)/
    Probably unchanged

    DOSE IN RENAL IMPAIRMENT


    GFR (mL/MIN)


  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES


  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    Unlikely dialysability. Dose as in
    normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :
    Unknown dialysability. Dose as in
    normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:
    Unlikely dialysability. Dose as in
    normal renal function

    IMPORTANT DRUG INTERACTIONS


    Potentially hazardous interactions with other drugs
    Dexamethasone: increased concentrations

    of metabolite of albendazole

    ADMINISTRATION


    Reconstition



    Route


    Oral

    Rate of Administration



    Comments



    OTHER INFORMATION


    Available on a named patient basis from

    IDIS (Zentel®)
    Undergoes first pass metabolism